A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.
In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.
Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer.
When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.
Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer therefore results in unnecessary biopsies and over-diagnosis and overtreatment of many men.
Circulating tumor cells
The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells, or circulating tumor cells (CTCs), that have left the original tumour and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient’s blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.
The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew’s Hospital in London.
The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.
When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 per cent accuracy, better than any previously reported biomarkers.
Additionally, the number and type of CTCs present in the blood was also indicative of the aggressiveness of the cancer. Focusing on more aggressive prostate cancer may reduce over-treatment and unnecessary biopsies for benign and non-aggressive conditions.
‘A paradigm shift in the way we diagnose prostate cancer’
Lead researcher Professor Yong-Jie Lu from Queen Mary’s Barts Cancer Institute said: “The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure.
“Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we’ve now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer.”
As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- New study says many behind on important cancer screeningson May 2, 2021 at 6:39 am
When the COVID pandemic hit and the country locked down, many Americans missed their scheduled screenings for cancer. A new study reveals just how many of these tests were skipped. Researchers from ...
- Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour controlon May 1, 2021 at 2:24 am
For localised prostate cancer, focal therapy offers an organ-sparing alternative to radical treatments (radiotherapy or prostatectomy). Currently, there is no randomised comparative effectiveness data ...
- Masitinib Plus Docetaxel Improves PFS in Metastatic Castration-Resistant Prostate Canceron April 30, 2021 at 11:14 am
The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic ...
- Thousands of men to trial new home test kit for prostate canceron April 30, 2021 at 12:47 am
Thousands of men worldwide are to receive a home test kit for prostate cancer – thanks to pioneering research from the University of East Anglia and the Norfolk and Norwich University Hospital (NNUH).
- DIY home testing kit that diagnoses prostate cancer trialled in Britainon April 29, 2021 at 4:05 pm
Researchers will post kits to 2,000 men in this country, Europe and Canada, with volunteers requested to send back two urine samples for laboratory analysis.
- Treatment Type a Non-Factor in Prostate Cancer Patients' Anxietyon April 29, 2021 at 2:05 pm
Incidence of anxiety among prostate cancer patients was similar, no matter what type of primary treatment they chose, a researcher said. No matter if prostate cancer patients underwent risk-based ...
- Decrease in prostate cancer diagnoses due to pandemicon April 29, 2021 at 9:42 am
During the first wave of the corona pandemic, 36 per cent fewer men were diagnosed with prostate cancer in Sweden than in previous years. On the other hand, the number of patients receiving curative ...
- City of Hope initiates Phase 2 clinical trial to investigate if mushroom tablets could slow prostate canceron April 28, 2021 at 11:33 pm
City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to ...
- City of Hope opens Phase 2 trial to test if mushroom tablets could slow prostate canceron April 28, 2021 at 9:00 pm
City of Hope, a cancer research and treatment center, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing white button mushroom extract could regulate the ...
- Veterans with Prostate Cancer Are Underassessed And Undertreated For Cardiovascular Risk Factorson April 28, 2021 at 8:12 am
A recent analysis of veterans with prostate cancer showed that they are not being assessed and treated for cardiovascular risk factors at the rate they should be to optimize survival, particularly ...
via Bing News